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Transport by Human Cytotrophoblasts from Normal
and Growth-Restricted Pregnancies
E. Vasilopoulou, L. S. Loubie`re, A. Martín-Santos, C. J. McCabe, J. A. Franklyn,
M. D. Kilby, and S.-Y. Chan
School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of
Birmingham, Birmingham B15 2TT, United Kingdom
Context:Abnormal placentation in human pregnancy is associatedwith intrauterine fetal growth
restriction (IUGR). Our group has previously reported the association between severe IUGR, lower
fetal circulating concentrations of thyroid hormones (THs), and altered expression of TH receptors
and TH transporters within human placental villi. We postulate that altered TH bioavailability to
trophoblasts may contribute to the pathogenesis of IUGR.
Design andObjective: Cytotrophoblasts were isolated from normal and IUGR human placentae to
compare their responsiveness to T3 and their capability for T3 transport.
Results: Compared with normal cytotrophoblasts, the viability of IUGR cytotrophoblasts (assessed
by methyltetrazoleum assay) was significantly reduced (P  0.001), whereas apoptosis (assessed
using caspase3/7activity andM30 immunoreactivity)was significantly increasedafter T3 treatment
for 48 h (P 0.001 and P 0.01, respectively). The secretion of human chorionic gonadotropinwas
significantly increased by IUGR cytotrophoblasts compared with normal cytotrophoblasts (P 
0.001), independently of T3 treatment. Net transport of [
125I]T3 was 20% higher by IUGR cytotro-
phoblasts compared with normal cytotrophoblasts (P  0.001), and this was accompanied by a
2-fold increase in the protein expression of the TH transporter, monocarboxylate transporter 8, as
assessed by Western immunoblotting (P  0.01).
Conclusions: IUGR cytotrophoblasts demonstrate altered responsiveness to T3 with significant
effects on cell survival and apoptosis compared with normal cytotrophoblasts. Increased mono-
carboxylate transporter 8 expression and intracellular T3 accumulation may contribute to the
altered T3 responsiveness of IUGR cytotrophoblasts. (J Clin EndocrinolMetab 95: 4762–4770, 2010)
Intrauterine growth restriction (IUGR) is a pregnancycomplication that is characterized by failure to achieve
the genetic growth potential of the fetus (1) and is asso-
ciated with significant perinatal morbidity and mortality
(2, 3). IUGR is often a multifactorial disease process (4)
but is commonly associatedwith abnormal placentalmor-
phology and maternal uteroplacental blood flow (5, 6).
The remodeling of maternal spiral arteries that facilitates
unobstructed blood flow from the maternal circulation
toward the placenta in normal pregnancies is abnormal in
IUGR pregnancies (7–10). Histological examination of
term placentae has revealed that the number of apoptotic
nuclei within villous syncytiotrophoblasts is increased in
human pregnancies complicated by IUGR (11–13). The
syncytialization of cytotrophoblasts into syncytiotropho-
blastwithin placental villi is also increased in IUGR, as dem-
onstrated in experiments using placental explants (14) and
primary cultures of term cytotrophoblasts (15).
Maternal thyroid status is oneof several factors that are
thought to be involved in human placental development.
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Untreated maternal hyperthyroidism has been associated
with complications of malplacentation, including IUGR,
placental abruption, and preeclampsia (16), whereas ma-
ternal subclinical hypothyroidism has been associated with
increased risks of miscarriage, placental abruption, and pre-
termdelivery (17, 18),which suggests some influence ofma-
ternal thyroid hormones (THs) on human placentation. In
vitro, T3, the active TH ligand, increases the invasive capa-
bility of first trimester human extravillous trophoblasts (19)
and suppresses apoptosis in this cell type (20).
Although circulating concentrations ofTHsare thema-
jor determinants of cellular TH supply, there are several
prerequisites for effective TH action, including TH trans-
port into cells and prereceptor regulation of T3, by iodo-
thyronine deiodinases and T3 binding to nuclear TH
receptors (TRs) that regulate the expression of TH-re-
sponsive genes (21). Our group has previously reported
changes in the mechanisms regulating TH action in pla-
centae from severe IUGR pregnancies delivered in the
early third trimester. The protein expression of the TR
isoformsTR1, TR2, andTR1 is increased in placental
villi from severe IUGR pregnancies (22) with no signifi-
cant change in the activities of placental deiodinase types
2 and 3 (23). In addition, the expression of the TH trans-
porter monocarboxylate transporter 8 (MCT8; official
symbol, SLC16A2) is increased,whereas the expression of
MCT10 (SLC16A10) is decreased in the villous placenta
with severe IUGR (24, 25). Using percutaneous in utero
fetal blood sampling, we have also reported that the cir-
culating concentrations of free T4 and free T3 are signif-
icantly reduced in severely growth restricted fetuses (22).
We hypothesize that the reported changes in the ex-
pression of TRs and TH transporters in IUGR placentae
may be associated with altered trophoblast sensitivity to
THs in IUGR pregnancies. In this study, primary cultures
of cytotrophoblasts isolated from third trimester placen-
tae from uncomplicated pregnancies (normal cytotropho-
blasts) or from pregnancies complicated by IUGR (IUGR
cytotrophoblasts) were used to assess differences in T3
responsiveness and to investigate whether changes in TH
transport may account for such differences.
Subjects and Methods
Sample collection
Human placentae from normal (n 27) and IUGR (n 14)
pregnancies were collected with informed written consent and
local research ethics committee approval after elective delivery
by cesarean section. All were delivered after 35 completedweeks
of gestation, as determined by a first trimester ultrasound scan of
crown-rump length. The IUGR cases were diagnosed prospec-
tively using ultrasound and had at least two of the following
characteristics: 1) abdominal circumference, measured by ultra-
sound, less than the 10th centile for gestation; 2) abdominal
circumference growth velocity of less than 1.5 SD values over
14 d; 3) oligohydramnios, defined asmaximumpool depth of 10th
centile or less for gestation; and 4) absent or increased resistance
index in theenddiastolic flowvelocityof theumbilicalarteryDopp-
ler velocity waveform. The IUGR fetuses were not known to have
abnormal karyotypes, and none of the pregnancies was compli-
cated by maternal hypertension or thyroid disorders.
Trophoblast isolation and culture
Villous cytotrophoblasts were isolated as described previ-
ously (26–28). Isolated cytotrophoblasts were cultured in
DMEM:F12 nutrient mixture (1:1), supplemented with 1000
U/liter penicillin, 0.001% (wt/vol) streptomycin, 0.029% (wt/
vol) L-glutamine (all from Invitrogen, Paisley, UK), and 0.005%
(wt/vol) gentamicin (Sigma-Aldrich, Dorset, UK). The medium
was supplemented with 10% fetal calf serum (FCS; Invitrogen)
or with 10% charcoal-stripped FCS (First Link, Birmingham,
UK) for cells that would be subsequently treated with T3.
Assessment of cell survival and apoptosis
Cytotrophoblastswere seeded in96-well plates (3105 cells/
well) and 18 h after isolation were treated with 0, 1, 10, or 100
nMT3 for 48 h. Cell survival was assessed in four replicates using
themethyltetrazoleum (MTT; Sigma-Aldrich) assay as described
previously (26). Cell apoptosis was assessed in triplicate using
the luminescence-based caspase 3/7 activity assay (Promega,
Southampton,UK)asdescribedpreviously (29).The resultswere
normalized to the values obtained with no T3 treatment (0 nM)
within each experiment. In addition, apoptosis in response to T3
was assessed with immunofluorescent staining for the apoptotic
marker,M30 (30). Cytotrophoblasts were seeded in duplicate in
24-well plates (7.5 105 cells/well) and 48 h after T3 treatment
were fixed and permeabilized with 100% methanol. Cytotro-
phoblasts were probed with primary antibody against M30 (1:
50; Roche, Burgess Hill, UK), followed by Alexa Fluor 488-
conjugated secondary antibody (1:250; Invitrogen) and the
nuclear stain, Hoechst 33258 (1:1000; Sigma-Aldrich). M30
staining was assessed by a researcher blinded to placental type
and treatment. The number of nuclei with M30 perinuclear
staining was expressed as a percentage of the total number of
nuclei. The results were normalized within each experiment to
the average percentage of M30-positive nuclei with no T3 treat-
ment (0 nM).
Human chorionic gonadotropin (hCG) secretion
Cytotrophoblasts were seeded in 12-well plates (1.5  106
cells/well) and 18 h after isolation were treated with 0 or 10 nM
T3. Culture media and protein were collected at 0, 48, and 72 h
after treatment. Secretion of hCGwas assessed in duplicate using
an ELISA kit (DRG, Marburg, Germany) according to manu-
facturer’s guidelines. Results were expressed as milli-interna-
tional units of hCG, per hour in culture, permilliliter ofmedium,
per milligram of protein (27), and the rise in hCG secretion be-
tween 0 and 48 or 0 and 72 h after treatment was calculated.
T3 uptake and efflux
T3 uptake
Cytotrophoblasts were cultured in duplicate in 10% FCS-
supplemented medium in 12-well plates for 66 h (1.5  106
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cells/well). After incubation for 0, 5, 10, or 30 min with serum
free medium (SFM) supplemented with 1 nM T3 containing ap-
proximately 2  105 cpm of [125I]T3 (Perkin-Elmer, Wellesley,
MA), cytotrophoblasts were rapidly washed three times with
ice-cold SFM with 0.1% BSA and were lysed with 2% sodium
dodecyl sulfate (SDS). The radioactivity in the cell lysates (cel-
lular radioactivity) was measured using a -counter and ex-
pressedasapercentageof the total radioactivity in the incubation
media, which was added to the cells initially (31) (Supplemental
Fig. 1, published on The Endocrine Society’s Journals Online
web site at http://jcem.endojournals.org).
T3 efflux
Cytotrophoblasts were incubated in duplicate with SFM sup-
plementedwith1nMT3containing [
125I]T3 (210
5cpm/0.5ml)
for 10 min. Cytotrophoblasts were briefly washed with SFM
with 0.1% BSA and incubated in SFM without T3 (efflux me-
dium) for 0, 1, 2, 5, or 10 min. The medium was then removed,
and cytotrophoblasts were lysed with 2% SDS. The propor-
tion of the radioactivity that was retained in the cell lysates
compared with that added to the cells initially was calculated.
T3 efflux was expressed as a percentage of the cellular radio-
activity normalized to time 0 (just before the addition of efflux
medium) (31).
Quantitative TaqMan PCR
Cytotrophoblasts were cultured in 35-mm2 tissue culture
dishes (3  106 cells/dish) in 10% FCS-supplemented medium.
Total RNA was extracted at 18 or 66 h after culture with TRI
reagent (Ambion, Warrington, UK) following the manufactur-
er’s guidelines. RNA (1 g) was reverse-transcribed using avian
myeloblastosis virus reverse transcriptase (Promega, Madison,
WI) in a total reaction volume of 20 l following the manufac-
turer’s guidelines. Expression ofmRNAencoding TH transport-
ers MCT8 and MCT10; the system L-amino acid transporters
LAT1 (SLC7A5), LAT2 (SLC7A8), CD98 (SLC3A2); and the
organic anion-transporting polypeptides OATP1A2 (SLCO1A2)
orOATP4A1(SLCO4A1)wasdeterminedandnormalized to the
expression of the housekeeping gene, 18S, as an internal control
using the ABI PRISM 7500 Sequence Detection System (ABI,
Foster City, CA) using validated primers and probes as previ-
ously described (25). Relative quantification of each gene was
determined using the Ct method as previously described (25).
The relative mRNA expression for each sample was compared
with the mean gene expression in normal cytotrophoblasts at
18 h after culture that was assigned the arbitrary value of 1.
MCT8 and MCT10 antibody production and
Western immunoblotting
Rabbit polyclonal antisera for human MCT8 (Ab4790; Sig-
ma-Genosys, Haverhill, UK) and MCT10 (Ab2198; Charles
River Laboratories, Kisslegg, Germany) were raised against syn-
thetic polypeptides comprising amino acids 79-92 (SQASEE-
AKGPWQEA) and 503-515 (SSGMFKKESDSII), respectively,
each conjugated to keyhole limpet hemocyanin. Antisera from
final bleeds were affinity-purified and their specificity con-
firmed (Fig. 1).
Protein was extracted from IUGR and normal cytotropho-
blasts cultured for 18or66h in10%FCS-supplementedmedium
using 2% SDS, and Western immunoblotting was performed as
previously described (25). Briefly, protein (30g)was denatured
(1 h at room temperature) in Laemmli buffer (Bio-Rad, Hert-
fordshire, UK) with 350 mM dithiothreitol, separated by elec-
trophoresis in 8% SDS-PAGE gels, and blotted onto nitrocellu-
lose membranes. The blots were incubated with the MCT8 (3.2
g/ml) or theMCT10 (5.2g/ml) antibody followed by second-
aryhorseradishperoxidase-conjugatedantibody (1:2000;Dako,
Glostrup, Denmark). Antigen-antibody complexes were visual-
ized using the ECL chemiluminescence detection system (GE
Healthcare, St.Giles,UK). Expressionof-actinwasdetermined
to assess protein loading.
Statistical analysis
Data were analyzed using the Minitab statistical software
(version 15; Minitab Inc., State College, PA). For demographic
data, theMann-WhitneyU test was used to compare continuous
variables, and the Fisher’s exact test was used to analyze con-
tingency tables. For other data sets, ANOVA was performed
using the general linear model followed by Tukey all pairwise
multiple comparison post hoc tests to assess differences be-
tween individual groups. Residuals (differences between the
observed values and the predicted values by the general linear
model) for all data sets passed the normality test as determined
using the Kolmogorov-Smirnov test, except for the hCG se-
cretion data, which, thus required logarithmic transformation
before statistical analysis. For all tests, significance was taken
as P  0.05.
FIG. 1. Western immunoblotting confirming the specificity of
polyclonal antibodies to MCT8 and MCT10. A, MCT8 4790 antibody.
Whole cell protein extracts of MCT8-null JEG3 cells transfected with
either vector only (VO) or a plasmid encoding human MCT8 and
homogenates of term placenta tissue (Term PL) expressing endogenous
MCT8 were probed with the MCT8 antibody (1.6 g/ml) after
preincubation with or without the blocking peptide (BP). B, MCT10
2198 antibody. Whole cell protein extracts of HTR8/SVNeo cells (with
very low endogenous MCT10 mRNA expression) transfected with
either VO or a plasmid encoding human MCT10 and extracts from
normal cytotrophoblasts (CTs) that were cultured for 18 h were probed
with the MCT10 antibody (5.2 g/ml) after preincubation with or
without the blocking peptide (BP). Bands of approximately 60 kDa for
MCT8 (A) and approximately 50 kDa for MCT10 (B) are seen,
consistent with their predicted molecular weights, respectively.
Immunoreactivity for -actin was used to assess protein loading.
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Results
Clinical characteristics of study groups
Comparing the demographic data of the normal and
IUGR cohorts, there was no significant difference in the
maternal age, proportion of cigarette smokers, parity, and
fetal sex (Table 1).However, themedian gestational ageof
delivery in the IUGR cohort was 1 wk less than in the
normal (P  0.001). As expected, the birth weights and
placental weights of the IUGR group were significantly
lower (P  0.001 and P  0.01, respectively) compared
with the normal group. The birthweight percentile, which
was calculated using customized growth charts and ac-
counts for parity, ethnicity, maternal BMI, gestational
age, and fetal sex (32), was also significantly lower in the
IUGR group (P  0.001), with a median of the 2nd per-
centile compared with the 53rd percentile for the normal
group.
Survival of cytotrophoblasts in response to T3
Because cytotrophoblasts do not proliferate in vitro,
the MTT assay was used as a measure of cell survival.
Overall, IUGR cytotrophoblasts survived less compared
with normal cytotrophoblasts in response to T3 treatment
(Fig. 2A; P  0.001). Post hoc analysis revealed that this
differencewas significant when the cells were treatedwith
1 nM T3 (20% reduction; P 0.01). There was no differ-
ence in the survival of normal and IUGR cytotrophoblasts
in the absence of T3 (data not shown).
Cytotrophoblast apoptosis in response to T3
We then assessed whether the effect of T3 on cytotro-
phoblast survival wasmediated via increased apoptosis in
IUGR cytotrophoblasts. Caspase 3/7 activity after T3
treatment was increased in IUGR compared with normal
cytotrophoblasts (Fig. 2B;P0.001). Similar towhatwas
observed with cytotrophoblast survival, the difference in
caspase 3/7 activity between normal and IUGR cytotro-
phoblastswas particularly significant after treatmentwith
1 or 100 nM T3 (27% increase for both; P  0.01). The
T3-mediated increase in apoptosis of IUGR cytotropho-
blasts compared with normal cytotrophoblasts was also
confirmed by immunostaining for M30 (Fig. 2C), which
demonstrated a highly statistically significant difference
between normal and IUGR cytotrophoblasts overall (P
0.01). The greatest increase in apoptosis of IUGR cytotro-
phoblasts compared with normal cytotrophoblasts oc-
curredafter treatmentwith100nMT3 (53%increase), and
posthoc tests found this tobe just close to significance (P
0.058). A comparison of apoptosis in normal and IUGR
cytotrophoblasts in the absence of T3 revealed no signif-
icant differences (data not shown).
hCG secretion from cytotrophoblasts in
response to T3
Overall, the rise in hCG secretion over time was higher
in IUGR compared with normal cytotrophoblasts (P 
0.001; Fig. 3). Post hoc tests demonstrated that this effect
was significant in both the absence (P  0.001) and the
presence (P  0.01) of T3.
T3 transport by cytotrophoblasts
These results suggested that T3 affects the behavior of
cytotrophoblasts isolated fromIUGRbutnot fromnormal
placentae with respect to survival and apoptosis. This ef-
fect could be mediated via differences in intracellular
availability of T3. To explore this possibility, we assessed
T3 transport by IUGR or normal cytotrophoblasts main-
tained in culture for 66 h. T3 uptake was higher by IUGR
compared with normal cytotrophoblasts (P 0.001; Fig.
4A). Post hoc tests demonstrated that this difference was
TABLE 1. Clinical characteristics of normal and IUGR study groups
Normal
(n  27)
IUGR
(n  14) P value
Maternal data
Age (yr) 32.0 (21–41) 31.5 (24–44) NS
Smokers 3/27 (11) 4/14 (28) NS
Nulliparous 3/27 (11) 5/14 (36) NS
Fetal data
Males 9/27 (33) 5/14 (36) NS
Gestational age (wk) 39 (37–40) 38 (35–40) 0.0006
Birth weight (g) 3320 (2320–4400) 2400 (1565–2960) 0.0001
Placenta weight (g) 640 (509–883) 464 (313–700) 0.0012
Customized birth weight percentile 53 (23–99) 2 (0–27) 0.0001
Abnormal umbilical artery Doppler flow 0/27 (0) 3/14 (21) 0.0341
Oligohydramnios 0/27 (0) 8/14 (57) 0.0001
Values represent ratio (%) or median (range). In the IUGR group, 1) one neonate was diagnosed with Prader-Willi syndrome at 8 months of age; 2)
one woman was epileptic and was treated with a low dose of lamotrigine (100 mg twice daily); and 3) another woman was a heroin addict who
had been taking reducing doses of methadone during pregnancy. NS, Not statistically significant.
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only statistically significant after incubation with [125I]T3
for 30 min (23% increase; P  0.001), indicating that
there is an increase in net T3 transport by the cells rather
than T3 uptake per se. In contrast, T3 efflux over a period
of 10min was similar between normal and IUGR cytotro-
phoblasts (Fig. 4B). These results therefore suggest that
intracellular accumulation of T3 is higher in IUGR com-
pared with normal cytotrophoblasts.
MCT8 and MCT10 expression in normal and IUGR
cytotrophoblasts
Changes in the expression of TH transporters may ac-
count for the altered T3 transport in IUGR cytotropho-
FIG. 4. T3 transport by normal and IUGR cytotrophoblasts. A, T3
uptake. Cytotrophoblasts were incubated with 1 nM T3 containing
2  105 cpm [125I]T3 for 5 to 30 min, and the amount of cellular
radioactivity was assessed (normal, n  7; IUGR, n  5). B, T3 efflux.
Cytotrophoblasts were incubated for 10 min with 1 nM T3 containing
2  105 cpm [125I]T3 and after brief washing were incubated with SFM
without T3 (efflux media) for 0 to 10 min. The amount of radioactivity
that was retained intracellularly was assessed and expressed as a
percentage of the cellular radioactivity before the addition of efflux
media (0 min) (normal, n  6; IUGR, n  5). ***, P  0.001.
FIG. 2. Effect of T3 on the survival and apoptosis of normal and IUGR
cytotrophoblasts. Survival and apoptosis were assessed after 48 h of
treatment with 0, 1, 10, or 100 nM T3. Within each experiment, results
were compared with that after no T3 treatment (0 nM), which was
given an arbitrary value of 100%. A, Cytotrophoblast survival assessed
using the MTT assay (normal, n  9; IUGR, n  5). B, Apoptosis
assessed using the caspase 3/7 activity assay (normal, n  9; IUGR,
n  5). C, Apoptosis assessed by immunofluorescent staining for M30
(normal, n  4; IUGR, n  3). **, P  0.01; ***, P  0.001.
FIG. 3. Effect of T3 on hCG secretion by normal and IUGR
cytotrophoblasts. The hCG secretion at 48 h after T3 treatment
(normal, n  9; IUGR, n  6) and 72 h after T3 treatment (normal, n 
8; IUGR, n  6) was assessed and normalized to the hCG secretion at
0 h of T3 treatment (18 h after culture), which was given an arbitrary
value of 100%. **, P  0.01; ***, P  0.001.
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blasts. In previous studies, we have reported that the ex-
pression of MCT8 andMCT10 is altered in IUGR villous
placental biopsies,which consist ofmultiple cell types (24,
25).We thus sought to investigate the mRNA and protein
expression of MCT8 and MCT10 in primary cultures of
IUGR and normal cytotrophoblasts after 18 h of culture
(presyncytialization) or 66 h (postsyncytialization). There
were no differences in the expression ofMCT8orMCT10
mRNA in IUGR compared with normal cytotrophoblasts
at both 18 and 66 h after culture (Fig. 5, A and B). How-
ever, Western immunoblottings and their quantification
by relative densitometry demonstrated that MCT8 pro-
tein expression was higher in IUGR compared with nor-
mal cytotrophoblasts (P  0.01) (Fig. 5C), most signifi-
cantly at 18 h by 2.1-fold (P 0.05). In
contrast, there was no difference in the
protein expression of MCT10 between
IUGR and normal cytotrophoblasts
(Fig. 5D). In addition, overall the ex-
pression of MCT8 and MCT10 in cy-
totrophoblasts decreased significantly
between 18 and 66 h after culture at
both the mRNA (P  0.001) and
protein (MCT8, P  0.001; MCT10,
P 0.05) levels. Relative quantification
of the mRNA encoding the TH trans-
porters OATP1A2, OATP4A1, LAT1,
LAT2, and CD98, which have been re-
ported in the human placenta, revealed
no significant differences between IUGR
and normal cytotrophoblasts (data
not shown).
Discussion
In this study, we have demonstrated
that whereas cytotrophoblasts isolated
from normal placentae are unaffected
byT3 treatment, cytotrophoblasts from
IUGR placentae are responsive to T3 in
terms of cell survival and apoptosis.
This effect is associated with increased
accumulation of intracellular T3 in
IUGR cytotrophoblasts and increased
protein expression of the TH trans-
porter, MCT8. In this report, we show
for the first time that the previously
documented increase in apoptosis by
IUGR placentae (11–15) may be partly
mediated by T3.
In accordance with our previous
study (26), we have confirmed that T3
does not affect the survival of normal cytotrophoblasts. In
contrast, T3 adversely affects the survival of IUGR cy-
totrophoblasts.We also demonstrated that T3 induces ap-
optosis in IUGR, but not in normal cytotrophoblasts in
vitro, indicating that the effect of T3 on the survival of
IUGR cytotrophoblasts may be mediated via increased
apoptosis. The regulation of apoptosis in the villous tro-
phoblast is important for normal placental development.
The syncytiotrophoblast layer of the placenta,which is the
cell barrier that controls transplacental transport, is con-
tinuously renewed by cytotrophoblasts fusing into adja-
cent syncytiotrophoblast, whereas aged syncytiotropho-
blast nuclei are extruded into the maternal circulation as
FIG. 5. MCT8 andMCT10 expression in primary cultures of normal and IUGR cytotrophoblasts.
Relative expression of MCT8 (A) and MCT10 (B) mRNA (mean  SEM) was assessed at 18 and
66 h after culture. The mean mRNA expression in normal samples at 18 h after culture was
given an arbitrary value of 1 (normal, n  8; IUGR, n  8). Western immunoblotting for
MCT8 (C1) and MCT10 (D1) on whole protein lysates obtained at 18 and 66 h after culture.
Bands representing MCT8 and MCT10 were detected at approximately 60 and 50 kDa,
respectively. Immunoblotting for -actin on the same membranes was used to assess
protein loading. The protein expression of MCT8 (C2; normal, n  6; IUGR, n  5) and
MCT10 (D2; normal, n  3; IUGR, n  3) were quantified by relative densitometry and
shown as a ratio to -actin protein expression (mean  SEM). *, P  0.05; **, P  0.01;
***, P  0.001.
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“syncytial knots.” It is believed that this process is regu-
lated by apoptotic mechanisms (33). IUGR has been as-
sociated with increased apoptosis in the human placenta,
as demonstrated by more apoptotic nuclei seen histolog-
ically and increased caspase 3 activity in IUGR compared
with normal placentae, particularly in syncytiotropho-
blasts (11–13). It has been shown before that the IUGR
placenta is more susceptible to apoptotic stimuli such as
TNF- and hypoxia (14, 34). However, this is the first
study to show that T3 can also induce apoptosis in IUGR
cytotrophoblasts in vitro, whereas it has no effect on nor-
mal cytotrophoblasts.
Primary cultures of cytotrophoblasts isolated from
term placentae syncytialize with time in culture to form
multinucleate cells. This differentiation process is associ-
ated with increased secretion of hCG (28). Our finding of
increased hCG secretion by IUGR compared with normal
cytotrophoblasts is in agreement with other studies.
Crocker et al. (14) have found that hCG secretion was
higher from explants from IUGR placentae compared
with normal controls. Newhouse et al. (15) reported that
there was increased syncytialization of primary cytotro-
phoblast cultures from IUGR compared with normal pla-
centae assessed by immunofluorescent staining for des-
moplakin and by hCG secretion. A previous study by
Nishii et al. (35) suggested that treatment with 10 nM T3
promotes hCG secretion in cytotrophoblasts. In our
study, however, treatment with 10 nM T3 did not sig-
nificantly affect hCG secretion by either normal or
IUGR cytotrophoblasts.
TH transport may play a role in regulating the impact
of T3 on cytotrophoblasts via regulating intracellular T3
availability. We observed in vitro that net T3 transport is
increased in cytotrophoblasts from IUGR compared with
normal placentae at 66 h after culture, whereas T3 efflux
is unaltered, thus indicating that there is increased intra-
cellular accumulation of T3 in IUGR cytotrophoblasts,
which may contribute to their increased sensitivity to T3
treatment.The increased accumulationofT3within IUGR
cytotrophoblastsmaybedue to changes inTH transporter
expression, changes in T3-binding capacity within cy-
totrophoblasts, aswell as differences in individual cell vol-
ume due to the increased syncytialization of IUGR
cytotrophoblasts.
We have previously reported that the protein expres-
sion of MCT8 is increased in whole placental biopsies
from pregnancies complicated by severe IUGR requiring
delivery in the early third trimester compared with gesta-
tionallymatchedcontrols, butnot inplacentae fromIUGR
pregnancies delivered after 37wk (24, 25). In contrast, the
present results obtained using primary cultures of cytotro-
phoblasts (95% pure) revealed that MCT8 protein ex-
pression was also increased in cytotrophoblasts from late
third trimester IUGR placentae. This change was not ac-
companied by an increase in MCT8 mRNA expression
indicating that posttranscriptional or posttranslational
modulation occurs.We have previously reported such dis-
crepancies between mRNA and protein expression for
MCT8 (25), and similar findings have been reported for
other plasma membrane transporters (36).
Increased protein expression of MCT8 is likely to con-
tribute to the increased net T3 uptake observed in IUGR
cytotrophoblasts. AlthoughMCT8 can facilitate T3 efflux
(31), our findings suggest that T3 uptake may be the more
dominant role ofMCT8 in cytotrophoblasts.Althoughwe
found no changes in the mRNA or protein expression of
MCT10 or in themRNA expression of LATs orOATPs in
IUGR cytotrophoblasts, consistent with previous findings
in whole placental biopsies (25), we cannot exclude the
possibility that changes in the activity of these TH trans-
porters may also contribute to the increased net T3 uptake
by IUGR cytotrophoblasts. In addition, increased accu-
mulation of T3 within IUGR cytotrophoblasts may occur
as a result of the possible increased intracellular binding of
T3 to TR isoforms, TR1 and TR1, that have previously
been found to be expressed at increased levels in IUGR
placenta villi (22). If so, this could contribute to both in-
creased intracellular accumulation of T3 and increased
sensitivity of IUGR cytotrophoblasts to T3.
Unlike findings in central nervous system cell types
(37), treatment of term cytotrophoblasts with T3 concen-
trationswithin the physiological range (10nMor less) does
not alter the expression of the deiodinase enzymes, D2
(activates T4 to T3) and D3 (inactivates T3) (23). Further-
more, no significant changes were observed in D2 and D3
mRNA expression and activity in biopsies from normal
compared with IUGR placentae (23). This suggests that
cytotrophoblasts cannot modulate intracellular T3 con-
centration through alterations in D2 and D3 activities,
thus rendering IUGRcytotrophoblastsmore vulnerable to
the increased net T3 uptake demonstrated in this current
study.
The increased T3 responsiveness of IUGR cytotropho-
blasts could be a contributing factor to the underlying
pathogenesis of IUGR or a consequence of this malpla-
centation syndrome. Maternal hyperthyroidism is one of
the endocrine factors that havebeenassociatedwith IUGR
(16), suggesting that increased exposure to TH may be
detrimental to fetoplacental development. Outside the
context of maternal thyroid disorders, our findings that
there is increased T3 accumulation within IUGR cytotro-
phoblasts and that T3 can adversely affect the survival and
increase apoptosis of these cells raise thepossibility that an
abnormallyhighT3concentration locally formspartof the
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dysregulated endocrine, paracrine, andautocrine environ-
ment, which occurs within the placenta in IUGR pregnan-
cies. Further investigation into the possible etiologies and
pathophysiology of altered T3 responsiveness within pla-
cental trophoblasts in IUGR is warranted.
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ne
r 
un
de
r 
co
py
ri
gh
t 
la
w
 o
r 
ot
he
r 
ap
pl
ic
ab
le
 la
w
s.
  
3
. 
Li
ce
n
se
 G
ra
n
t.
 S
ub
je
ct
 t
o 
th
e 
te
rm
s 
an
d 
co
nd
iti
on
s 
of
 t
hi
s 
Li
ce
ns
e,
 L
ic
en
so
r 
he
re
by
 g
ra
nt
s 
Yo
u 
a 
w
or
ld
w
id
e,
 r
oy
al
ty
-f
re
e,
 n
on
-e
xc
lu
si
ve
, 
pe
rp
et
ua
l (
fo
r 
th
e 
du
ra
tio
n 
of
 t
he
 a
pp
lic
ab
le
 
co
py
ri
gh
t)
 li
ce
ns
e 
to
 e
xe
rc
is
e 
th
e 
ri
gh
ts
 in
 t
he
 W
or
k 
as
 s
ta
te
d 
be
lo
w
: 
 
a.
to
 r
ep
ro
du
ce
 t
he
 W
or
k,
 t
o 
in
co
rp
or
at
e 
th
e 
W
or
k 
in
to
 o
ne
 o
r 
m
or
e 
C
ol
le
ct
iv
e 
W
or
ks
, 
an
d 
to
 r
ep
ro
du
ce
 t
he
 W
or
k 
as
 in
co
rp
or
at
ed
 in
 t
he
 C
ol
le
ct
iv
e 
W
or
ks
; 
 
b.
to
 c
re
at
e 
an
d 
re
pr
od
uc
e 
D
er
iv
at
iv
e 
W
or
ks
; 
 
c.
to
 d
is
tr
ib
ut
e 
co
pi
es
 o
r 
ph
on
or
ec
or
ds
 o
f,
 d
is
pl
ay
 p
ub
lic
ly
, 
pe
rf
or
m
 p
ub
lic
ly
, 
an
d 
pe
rf
or
m
 p
ub
lic
ly
 b
y 
m
ea
ns
 o
f 
a 
di
gi
ta
l a
ud
io
 t
ra
ns
m
is
si
on
 t
he
 W
or
k 
in
cl
ud
in
g 
as
 
in
co
rp
or
at
ed
 in
 C
ol
le
ct
iv
e 
W
or
ks
; 
 
d.
to
 d
is
tr
ib
ut
e 
co
pi
es
 o
r 
ph
on
or
ec
or
ds
 o
f,
 d
is
pl
ay
 p
ub
lic
ly
, 
pe
rf
or
m
 p
ub
lic
ly
, 
an
d 
pe
rf
or
m
 p
ub
lic
ly
 b
y 
m
ea
ns
 o
f 
a 
di
gi
ta
l a
ud
io
 t
ra
ns
m
is
si
on
 D
er
iv
at
iv
e 
W
or
ks
; 
 
Th
e 
ab
ov
e 
ri
gh
ts
 m
ay
 b
e 
ex
er
ci
se
d 
in
 a
ll 
m
ed
ia
 a
nd
 f
or
m
at
s 
w
he
th
er
 n
ow
 k
no
w
n 
or
 h
er
ea
ft
er
 
de
vi
se
d.
 T
he
 a
bo
ve
 r
ig
ht
s 
in
cl
ud
e 
th
e 
ri
gh
t 
to
 m
ak
e 
su
ch
 m
od
ifi
ca
tio
ns
 a
s 
ar
e 
te
ch
ni
ca
lly
 
ne
ce
ss
ar
y 
to
 e
xe
rc
is
e 
th
e 
ri
gh
ts
 in
 o
th
er
 m
ed
ia
 a
nd
 f
or
m
at
s.
 A
ll 
ri
gh
ts
 n
ot
 e
xp
re
ss
ly
 g
ra
nt
ed
 b
y 
Li
ce
ns
or
 a
re
 h
er
eb
y 
re
se
rv
ed
, 
in
cl
ud
in
g 
bu
t 
no
t 
lim
ite
d 
to
 t
he
 r
ig
ht
s 
se
t 
fo
rt
h 
in
 S
ec
tio
ns
 4
(d
) 
an
d 
4(
e)
. 
4
. 
R
es
tr
ic
ti
o
n
s.
Th
e 
lic
en
se
 g
ra
nt
ed
 in
 S
ec
tio
n 
3 
ab
ov
e 
is
 e
xp
re
ss
ly
 m
ad
e 
su
bj
ec
t 
to
 a
nd
 li
m
ite
d 
by
 t
he
 f
ol
lo
w
in
g 
re
st
ri
ct
io
ns
: 
 
a.
Yo
u 
m
ay
 d
is
tr
ib
ut
e,
 p
ub
lic
ly
 d
is
pl
ay
, 
pu
bl
ic
ly
 p
er
fo
rm
, 
or
 p
ub
lic
ly
 d
ig
ita
lly
 p
er
fo
rm
 
th
e 
W
or
k 
on
ly
 u
nd
er
 t
he
 t
er
m
s 
of
 t
hi
s 
Li
ce
ns
e,
 a
nd
 Y
ou
 m
us
t 
in
cl
ud
e 
a 
co
py
 o
f,
 o
r 
th
e 
U
ni
fo
rm
 R
es
ou
rc
e 
Id
en
tif
ie
r 
fo
r,
 t
hi
s 
Li
ce
ns
e 
w
ith
 e
ve
ry
 c
op
y 
or
 p
ho
no
re
co
rd
 o
f 
th
e 
W
or
k 
Yo
u 
di
st
ri
bu
te
, 
pu
bl
ic
ly
 d
is
pl
ay
, 
pu
bl
ic
ly
 p
er
fo
rm
, 
or
 p
ub
lic
ly
 d
ig
ita
lly
 
pe
rf
or
m
. 
Yo
u 
m
ay
 n
ot
 o
ff
er
 o
r 
im
po
se
 a
ny
 t
er
m
s 
on
 t
he
 W
or
k 
th
at
 a
lte
r 
or
 r
es
tr
ic
t 
th
e 
te
rm
s 
of
 t
hi
s 
Li
ce
ns
e 
or
 t
he
 r
ec
ip
ie
nt
s'
 e
xe
rc
is
e 
of
 t
he
 r
ig
ht
s 
gr
an
te
d 
he
re
un
de
r.
 Y
ou
 m
ay
 n
ot
 s
ub
lic
en
se
 t
he
 W
or
k.
 Y
ou
 m
us
t 
ke
ep
 in
ta
ct
 a
ll 
no
tic
es
 t
ha
t 
re
fe
r 
to
 t
hi
s 
Li
ce
ns
e 
an
d 
to
 t
he
 d
is
cl
ai
m
er
 o
f 
w
ar
ra
nt
ie
s.
 Y
ou
 m
ay
 n
ot
 d
is
tr
ib
ut
e,
 
pu
bl
ic
ly
 d
is
pl
ay
, 
pu
bl
ic
ly
 p
er
fo
rm
, 
or
 p
ub
lic
ly
 d
ig
ita
lly
 p
er
fo
rm
 t
he
 W
or
k 
w
ith
 a
ny
 
te
ch
no
lo
gi
ca
l m
ea
su
re
s 
th
at
 c
on
tr
ol
 a
cc
es
s 
or
 u
se
 o
f 
th
e 
W
or
k 
in
 a
 m
an
ne
r 
in
co
ns
is
te
nt
 w
ith
 t
he
 t
er
m
s 
of
 t
hi
s 
Li
ce
ns
e 
A
gr
ee
m
en
t.
 T
he
 a
bo
ve
 a
pp
lie
s 
to
 t
he
 
W
or
k 
as
 in
co
rp
or
at
ed
 in
 a
 C
ol
le
ct
iv
e 
W
or
k,
 b
ut
 t
hi
s 
do
es
 n
ot
 r
eq
ui
re
 t
he
 C
ol
le
ct
iv
e 
W
or
k 
ap
ar
t 
fr
om
 t
he
 W
or
k 
its
el
f 
to
 b
e 
m
ad
e 
su
bj
ec
t 
to
 t
he
 t
er
m
s 
of
 t
hi
s 
Li
ce
ns
e.
 I
f 
Yo
u 
cr
ea
te
 a
 C
ol
le
ct
iv
e 
W
or
k,
 u
po
n 
no
tic
e 
fr
om
 a
ny
 L
ic
en
so
r 
Yo
u 
m
us
t,
 t
o 
th
e 
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ro
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 C
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e 
N
C
 2
.0
.m
ht
ex
te
nt
 p
ra
ct
ic
ab
le
, 
re
m
ov
e 
fr
om
 t
he
 C
ol
le
ct
iv
e 
W
or
k 
an
y 
re
fe
re
nc
e 
to
 s
uc
h 
Li
ce
ns
or
 o
r 
th
e 
O
ri
gi
na
l A
ut
ho
r,
 a
s 
re
qu
es
te
d.
 I
f 
Yo
u 
cr
ea
te
 a
 D
er
iv
at
iv
e 
W
or
k,
 
up
on
 n
ot
ic
e 
fr
om
 a
ny
 L
ic
en
so
r 
Yo
u 
m
us
t,
 t
o 
th
e 
ex
te
nt
 p
ra
ct
ic
ab
le
, 
re
m
ov
e 
fr
om
 
th
e 
D
er
iv
at
iv
e 
W
or
k 
an
y 
re
fe
re
nc
e 
to
 s
uc
h 
Li
ce
ns
or
 o
r 
th
e 
O
ri
gi
na
l A
ut
ho
r,
 a
s 
re
qu
es
te
d.
  
b.
Yo
u 
m
ay
 n
ot
 e
xe
rc
is
e 
an
y 
of
 t
he
 r
ig
ht
s 
gr
an
te
d 
to
 Y
ou
 in
 S
ec
tio
n 
3 
ab
ov
e 
in
 a
ny
 
m
an
ne
r 
th
at
 is
 p
ri
m
ar
ily
 in
te
nd
ed
 f
or
 o
r 
di
re
ct
ed
 t
ow
ar
d 
co
m
m
er
ci
al
 a
dv
an
ta
ge
 o
r 
pr
iv
at
e 
m
on
et
ar
y 
co
m
pe
ns
at
io
n.
 T
he
 e
xc
ha
ng
e 
of
 t
he
 W
or
k 
fo
r 
ot
he
r 
co
py
ri
gh
te
d 
w
or
ks
 b
y 
m
ea
ns
 o
f 
di
gi
ta
l f
ile
-s
ha
ri
ng
 o
r 
ot
he
rw
is
e 
sh
al
l n
ot
 b
e 
co
ns
id
er
ed
 t
o 
be
 
in
te
nd
ed
 f
or
 o
r 
di
re
ct
ed
 t
ow
ar
d 
co
m
m
er
ci
al
 a
dv
an
ta
ge
 o
r 
pr
iv
at
e 
m
on
et
ar
y 
co
m
pe
ns
at
io
n,
 p
ro
vi
de
d 
th
er
e 
is
 n
o 
pa
ym
en
t 
of
 a
ny
 m
on
et
ar
y 
co
m
pe
ns
at
io
n 
in
 
co
nn
ec
tio
n 
w
ith
 t
he
 e
xc
ha
ng
e 
of
 c
op
yr
ig
ht
ed
 w
or
ks
. 
 
c.
If
 y
ou
 d
is
tr
ib
ut
e,
 p
ub
lic
ly
 d
is
pl
ay
, 
pu
bl
ic
ly
 p
er
fo
rm
, 
or
 p
ub
lic
ly
 d
ig
ita
lly
 p
er
fo
rm
 t
he
 
W
or
k 
or
 a
ny
 D
er
iv
at
iv
e 
W
or
ks
 o
r 
C
ol
le
ct
iv
e 
W
or
ks
, 
Yo
u 
m
us
t 
ke
ep
 in
ta
ct
 a
ll 
co
py
ri
gh
t 
no
tic
es
 f
or
 t
he
 W
or
k 
an
d 
gi
ve
 t
he
 O
ri
gi
na
l A
ut
ho
r 
cr
ed
it 
re
as
on
ab
le
 t
o 
th
e 
m
ed
iu
m
 o
r 
m
ea
ns
 Y
ou
 a
re
 u
til
iz
in
g 
by
 c
on
ve
yi
ng
 t
he
 n
am
e 
(o
r 
ps
eu
do
ny
m
 if
 
ap
pl
ic
ab
le
) 
of
 t
he
 O
ri
gi
na
l A
ut
ho
r 
if 
su
pp
lie
d;
 t
he
 t
itl
e 
of
 t
he
 W
or
k 
if 
su
pp
lie
d;
 t
o 
th
e 
ex
te
nt
 r
ea
so
na
bl
y 
pr
ac
tic
ab
le
, 
th
e 
U
ni
fo
rm
 R
es
ou
rc
e 
Id
en
tif
ie
r,
 if
 a
ny
, 
th
at
 
Li
ce
ns
or
 s
pe
ci
fie
s 
to
 b
e 
as
so
ci
at
ed
 w
ith
 t
he
 W
or
k,
 u
nl
es
s 
su
ch
 U
R
I 
do
es
 n
ot
 r
ef
er
 
to
 t
he
 c
op
yr
ig
ht
 n
ot
ic
e 
or
 li
ce
ns
in
g 
in
fo
rm
at
io
n 
fo
r 
th
e 
W
or
k;
 a
nd
 in
 t
he
 c
as
e 
of
 a
 
D
er
iv
at
iv
e 
W
or
k,
 a
 c
re
di
t 
id
en
tif
yi
ng
 t
he
 u
se
 o
f 
th
e 
W
or
k 
in
 t
he
 D
er
iv
at
iv
e 
W
or
k 
(e
.g
.,
 "
Fr
en
ch
 t
ra
ns
la
tio
n 
of
 t
he
 W
or
k 
by
 O
ri
gi
na
l A
ut
ho
r,
" 
or
 "
S
cr
ee
np
la
y 
ba
se
d 
on
 o
ri
gi
na
l W
or
k 
by
 O
ri
gi
na
l A
ut
ho
r"
).
 S
uc
h 
cr
ed
it 
m
ay
 b
e 
im
pl
em
en
te
d 
in
 a
ny
 
re
as
on
ab
le
 m
an
ne
r;
 p
ro
vi
de
d,
 h
ow
ev
er
, 
th
at
 in
 t
he
 c
as
e 
of
 a
 D
er
iv
at
iv
e 
W
or
k 
or
 
C
ol
le
ct
iv
e 
W
or
k,
 a
t 
a 
m
in
im
um
 s
uc
h 
cr
ed
it 
w
ill
 a
pp
ea
r 
w
he
re
 a
ny
 o
th
er
 
co
m
pa
ra
bl
e 
au
th
or
sh
ip
 c
re
di
t 
ap
pe
ar
s 
an
d 
in
 a
 m
an
ne
r 
at
 le
as
t 
as
 p
ro
m
in
en
t 
as
 
su
ch
 o
th
er
 c
om
pa
ra
bl
e 
au
th
or
sh
ip
 c
re
di
t.
  
d.
Fo
r 
th
e 
av
oi
da
nc
e 
of
 d
ou
bt
, 
w
he
re
 t
he
 W
or
k 
is
 a
 m
us
ic
al
 c
om
po
si
tio
n:
 
i.
P
er
fo
rm
an
ce
 R
o
ya
lt
ie
s 
U
n
d
er
 B
la
n
ke
t 
Li
ce
n
se
s.
 L
ic
en
so
r 
re
se
rv
es
 t
he
 e
xc
lu
si
ve
 r
ig
ht
 t
o 
co
lle
ct
, 
w
he
th
er
 in
di
vi
du
al
ly
 o
r 
vi
a 
a 
pe
rf
or
m
an
ce
 r
ig
ht
s 
so
ci
et
y 
(e
.g
. 
A
S
C
A
P,
 B
M
I,
 S
ES
A
C
),
 r
oy
al
tie
s 
fo
r 
th
e 
pu
bl
ic
 p
er
fo
rm
an
ce
 o
r 
pu
bl
ic
 d
ig
ita
l p
er
fo
rm
an
ce
 (
e.
g.
 w
eb
ca
st
) 
of
 t
he
 W
or
k 
if 
th
at
 p
er
fo
rm
an
ce
 is
 p
ri
m
ar
ily
 in
te
nd
ed
 f
or
 o
r 
di
re
ct
ed
 
to
w
ar
d 
co
m
m
er
ci
al
 a
dv
an
ta
ge
 o
r 
pr
iv
at
e 
m
on
et
ar
y 
co
m
pe
ns
at
io
n.
  
ii.
M
ec
h
an
ic
al
 R
ig
h
ts
 a
n
d
 S
ta
tu
to
ry
 R
oy
al
ti
es
. 
Li
ce
ns
or
 r
es
er
ve
s 
th
e 
ex
cl
us
iv
e 
ri
gh
t 
to
 c
ol
le
ct
, 
w
he
th
er
 in
di
vi
du
al
ly
 o
r 
vi
a 
a 
m
us
ic
 
ri
gh
ts
 a
ge
nc
y 
or
 d
es
ig
na
te
d 
ag
en
t 
(e
.g
. 
H
ar
ry
 F
ox
 A
ge
nc
y)
, 
ro
ya
lti
es
 
fo
r 
an
y 
ph
on
or
ec
or
d 
Yo
u 
cr
ea
te
 f
ro
m
 t
he
 W
or
k 
("
co
ve
r 
ve
rs
io
n"
) 
an
d 
di
st
ri
bu
te
, 
su
bj
ec
t 
to
 t
he
 c
om
pu
ls
or
y 
lic
en
se
 c
re
at
ed
 b
y 
17
 U
S
C
 
S
ec
tio
n 
11
5 
of
 t
he
 U
S
 C
op
yr
ig
ht
 A
ct
 (
or
 t
he
 e
qu
iv
al
en
t 
in
 o
th
er
 
ju
ri
sd
ic
tio
ns
),
 if
 Y
ou
r 
di
st
ri
bu
tio
n 
of
 s
uc
h 
co
ve
r 
ve
rs
io
n 
is
 p
ri
m
ar
ily
 
in
te
nd
ed
 f
or
 o
r 
di
re
ct
ed
 t
ow
ar
d 
co
m
m
er
ci
al
 a
dv
an
ta
ge
 o
r 
pr
iv
at
e 
m
on
et
ar
y 
co
m
pe
ns
at
io
n.
 
e.
W
eb
ca
st
in
g
 R
ig
h
ts
 a
n
d
 S
ta
tu
to
ry
 R
o
ya
lt
ie
s.
 F
or
 t
he
 a
vo
id
an
ce
 o
f 
do
ub
t,
 
w
he
re
 t
he
 W
or
k 
is
 a
 s
ou
nd
 r
ec
or
di
ng
, 
Li
ce
ns
or
 r
es
er
ve
s 
th
e 
ex
cl
us
iv
e 
ri
gh
t 
to
 
co
lle
ct
, 
w
he
th
er
 in
di
vi
du
al
ly
 o
r 
vi
a 
a 
pe
rf
or
m
an
ce
-r
ig
ht
s 
so
ci
et
y 
(e
.g
. 
S
ou
nd
Ex
ch
an
ge
),
 r
oy
al
tie
s 
fo
r 
th
e 
pu
bl
ic
 d
ig
ita
l p
er
fo
rm
an
ce
 (
e.
g.
 w
eb
ca
st
) 
of
 t
he
 
W
or
k,
 s
ub
je
ct
 t
o 
th
e 
co
m
pu
ls
or
y 
lic
en
se
 c
re
at
ed
 b
y 
17
 U
S
C
 S
ec
tio
n 
11
4 
of
 t
he
 U
S
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 C
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.m
ht
C
op
yr
ig
ht
 A
ct
 (
or
 t
he
 e
qu
iv
al
en
t 
in
 o
th
er
 j
ur
is
di
ct
io
ns
),
 if
 Y
ou
r 
pu
bl
ic
 d
ig
ita
l 
pe
rf
or
m
an
ce
 is
 p
ri
m
ar
ily
 in
te
nd
ed
 f
or
 o
r 
di
re
ct
ed
 t
ow
ar
d 
co
m
m
er
ci
al
 a
dv
an
ta
ge
 o
r 
pr
iv
at
e 
m
on
et
ar
y 
co
m
pe
ns
at
io
n.
  
5
. 
R
ep
re
se
n
ta
ti
on
s,
 W
ar
ra
n
ti
es
 a
n
d
 D
is
cl
ai
m
er
U
N
LE
S
S
 O
TH
ER
W
IS
E 
M
U
TU
A
LL
Y 
A
G
R
EE
D
 T
O
 B
Y 
TH
E 
PA
R
TI
ES
 I
N
 W
R
IT
IN
G
, 
LI
C
EN
S
O
R
 O
FF
ER
S
 
TH
E 
W
O
R
K
 A
S
-I
S
 A
N
D
 M
A
K
ES
 N
O
 R
EP
R
ES
EN
TA
TI
O
N
S
 O
R
 W
A
R
R
A
N
TI
ES
 O
F 
A
N
Y 
K
IN
D
 
C
O
N
C
ER
N
IN
G
 T
H
E 
W
O
R
K
, 
EX
PR
ES
S
, 
IM
PL
IE
D
, 
S
TA
TU
TO
R
Y 
O
R
 O
TH
ER
W
IS
E,
 I
N
C
LU
D
IN
G
, 
W
IT
H
O
U
T 
LI
M
IT
A
TI
O
N
, 
W
A
R
R
A
N
TI
ES
 O
F 
TI
TL
E,
 M
ER
C
H
A
N
TI
B
IL
IT
Y,
 F
IT
N
ES
S
 F
O
R
 A
 
PA
R
TI
C
U
LA
R
 P
U
R
PO
S
E,
 N
O
N
IN
FR
IN
G
EM
EN
T,
 O
R
 T
H
E 
A
B
S
EN
C
E 
O
F 
LA
TE
N
T 
O
R
 O
TH
ER
 D
EF
EC
TS
, 
A
C
C
U
R
A
C
Y,
 O
R
 T
H
E 
PR
ES
EN
C
E 
O
F 
A
B
S
EN
C
E 
O
F 
ER
R
O
R
S
, 
W
H
ET
H
ER
 O
R
 N
O
T 
D
IS
C
O
V
ER
A
B
LE
. 
S
O
M
E 
JU
R
IS
D
IC
TI
O
N
S
 D
O
 N
O
T 
A
LL
O
W
 T
H
E 
EX
C
LU
S
IO
N
 O
F 
IM
PL
IE
D
 W
A
R
R
A
N
TI
ES
, 
S
O
 S
U
C
H
 
EX
C
LU
S
IO
N
 M
A
Y 
N
O
T 
A
PP
LY
 T
O
 Y
O
U
. 
6
. 
Li
m
it
at
io
n
 o
n
 L
ia
b
ili
ty
. 
EX
C
EP
T 
TO
 T
H
E 
EX
TE
N
T 
R
EQ
U
IR
ED
 B
Y 
A
PP
LI
C
A
B
LE
 L
A
W
, 
IN
 N
O
 
EV
EN
T 
W
IL
L 
LI
C
EN
S
O
R
 B
E 
LI
A
B
LE
 T
O
 Y
O
U
 O
N
 A
N
Y 
LE
G
A
L 
TH
EO
R
Y 
FO
R
 A
N
Y 
S
PE
C
IA
L,
 
IN
C
ID
EN
TA
L,
 C
O
N
S
EQ
U
EN
TI
A
L,
 P
U
N
IT
IV
E 
O
R
 E
X
EM
PL
A
R
Y 
D
A
M
A
G
ES
 A
R
IS
IN
G
 O
U
T 
O
F 
TH
IS
 
LI
C
EN
S
E 
O
R
 T
H
E 
U
S
E 
O
F 
TH
E 
W
O
R
K
, 
EV
EN
 I
F 
LI
C
EN
S
O
R
 H
A
S
 B
EE
N
 A
D
V
IS
ED
 O
F 
TH
E 
PO
S
S
IB
IL
IT
Y 
O
F 
S
U
C
H
 D
A
M
A
G
ES
. 
 
7
. 
Te
rm
in
at
io
n
a.
Th
is
 L
ic
en
se
 a
nd
 t
he
 r
ig
ht
s 
gr
an
te
d 
he
re
un
de
r 
w
ill
 t
er
m
in
at
e 
au
to
m
at
ic
al
ly
 u
po
n 
an
y 
br
ea
ch
 b
y 
Yo
u 
of
 t
he
 t
er
m
s 
of
 t
hi
s 
Li
ce
ns
e.
 I
nd
iv
id
ua
ls
 o
r 
en
tit
ie
s 
w
ho
 h
av
e 
re
ce
iv
ed
 D
er
iv
at
iv
e 
W
or
ks
 o
r 
C
ol
le
ct
iv
e 
W
or
ks
 f
ro
m
 Y
ou
 u
nd
er
 t
hi
s 
Li
ce
ns
e,
 
ho
w
ev
er
, 
w
ill
 n
ot
 h
av
e 
th
ei
r 
lic
en
se
s 
te
rm
in
at
ed
 p
ro
vi
de
d 
su
ch
 in
di
vi
du
al
s 
or
 
en
tit
ie
s 
re
m
ai
n 
in
 f
ul
l c
om
pl
ia
nc
e 
w
ith
 t
ho
se
 li
ce
ns
es
. 
S
ec
tio
ns
 1
, 
2,
 5
, 
6,
 7
, 
an
d 
8 
w
ill
 s
ur
vi
ve
 a
ny
 t
er
m
in
at
io
n 
of
 t
hi
s 
Li
ce
ns
e.
  
b.
S
ub
je
ct
 t
o 
th
e 
ab
ov
e 
te
rm
s 
an
d 
co
nd
iti
on
s,
 t
he
 li
ce
ns
e 
gr
an
te
d 
he
re
 is
 p
er
pe
tu
al
 
(f
or
 t
he
 d
ur
at
io
n 
of
 t
he
 a
pp
lic
ab
le
 c
op
yr
ig
ht
 in
 t
he
 W
or
k)
. 
N
ot
w
ith
st
an
di
ng
 t
he
 
ab
ov
e,
 L
ic
en
so
r 
re
se
rv
es
 t
he
 r
ig
ht
 t
o 
re
le
as
e 
th
e 
W
or
k 
un
de
r 
di
ff
er
en
t 
lic
en
se
 
te
rm
s 
or
 t
o 
st
op
 d
is
tr
ib
ut
in
g 
th
e 
W
or
k 
at
 a
ny
 t
im
e;
 p
ro
vi
de
d,
 h
ow
ev
er
 t
ha
t 
an
y 
su
ch
 e
le
ct
io
n 
w
ill
 n
ot
 s
er
ve
 t
o 
w
ith
dr
aw
 t
hi
s 
Li
ce
ns
e 
(o
r 
an
y 
ot
he
r 
lic
en
se
 t
ha
t 
ha
s 
be
en
, 
or
 is
 r
eq
ui
re
d 
to
 b
e,
 g
ra
nt
ed
 u
nd
er
 t
he
 t
er
m
s 
of
 t
hi
s 
Li
ce
ns
e)
, 
an
d 
th
is
 
Li
ce
ns
e 
w
ill
 c
on
tin
ue
 in
 f
ul
l f
or
ce
 a
nd
 e
ff
ec
t 
un
le
ss
 t
er
m
in
at
ed
 a
s 
st
at
ed
 a
bo
ve
. 
 
8
. 
M
is
ce
ll
an
eo
u
s
a.
Ea
ch
 t
im
e 
Yo
u 
di
st
ri
bu
te
 o
r 
pu
bl
ic
ly
 d
ig
ita
lly
 p
er
fo
rm
 t
he
 W
or
k 
or
 a
 C
ol
le
ct
iv
e 
W
or
k,
 t
he
 L
ic
en
so
r 
of
fe
rs
 t
o 
th
e 
re
ci
pi
en
t 
a 
lic
en
se
 t
o 
th
e 
W
or
k 
on
 t
he
 s
am
e 
te
rm
s 
an
d 
co
nd
iti
on
s 
as
 t
he
 li
ce
ns
e 
gr
an
te
d 
to
 Y
ou
 u
nd
er
 t
hi
s 
Li
ce
ns
e.
  
b.
Ea
ch
 t
im
e 
Yo
u 
di
st
ri
bu
te
 o
r 
pu
bl
ic
ly
 d
ig
ita
lly
 p
er
fo
rm
 a
 D
er
iv
at
iv
e 
W
or
k,
 L
ic
en
so
r 
of
fe
rs
 t
o 
th
e 
re
ci
pi
en
t 
a 
lic
en
se
 t
o 
th
e 
or
ig
in
al
 W
or
k 
on
 t
he
 s
am
e 
te
rm
s 
an
d 
co
nd
iti
on
s 
as
 t
he
 li
ce
ns
e 
gr
an
te
d 
to
 Y
ou
 u
nd
er
 t
hi
s 
Li
ce
ns
e.
  
c.
If
 a
ny
 p
ro
vi
si
on
 o
f 
th
is
 L
ic
en
se
 is
 in
va
lid
 o
r 
un
en
fo
rc
ea
bl
e 
un
de
r 
ap
pl
ic
ab
le
 la
w
, 
it 
sh
al
l n
ot
 a
ff
ec
t 
th
e 
va
lid
ity
 o
r 
en
fo
rc
ea
bi
lit
y 
of
 t
he
 r
em
ai
nd
er
 o
f 
th
e 
te
rm
s 
of
 t
hi
s 
Li
ce
ns
e,
 a
nd
 w
ith
ou
t 
fu
rt
he
r 
ac
tio
n 
by
 t
he
 p
ar
tie
s 
to
 t
hi
s 
ag
re
em
en
t,
 s
uc
h 
pr
ov
is
io
n 
sh
al
l b
e 
re
fo
rm
ed
 t
o 
th
e 
m
in
im
um
 e
xt
en
t 
ne
ce
ss
ar
y 
to
 m
ak
e 
su
ch
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. 
 
d.
N
o 
te
rm
 o
r 
pr
ov
is
io
n 
of
 t
hi
s 
Li
ce
ns
e 
sh
al
l b
e 
de
em
ed
 w
ai
ve
d 
an
d 
no
 b
re
ac
h 
co
ns
en
te
d 
to
 u
nl
es
s 
su
ch
 w
ai
ve
r 
or
 c
on
se
nt
 s
ha
ll 
be
 in
 w
ri
tin
g 
an
d 
si
gn
ed
 b
y 
th
e 
pa
rt
y 
to
 b
e 
ch
ar
ge
d 
w
ith
 s
uc
h 
w
ai
ve
r 
or
 c
on
se
nt
. 
 
e.
Th
is
 L
ic
en
se
 c
on
st
itu
te
s 
th
e 
en
tir
e 
ag
re
em
en
t 
be
tw
ee
n 
th
e 
pa
rt
ie
s 
w
ith
 r
es
pe
ct
 t
o 
th
e 
W
or
k 
lic
en
se
d 
he
re
. 
Th
er
e 
ar
e 
no
 u
nd
er
st
an
di
ng
s,
 a
gr
ee
m
en
ts
 o
r 
re
pr
es
en
ta
tio
ns
 w
ith
 r
es
pe
ct
 t
o 
th
e 
W
or
k 
no
t 
sp
ec
ifi
ed
 h
er
e.
 L
ic
en
so
r 
sh
al
l n
ot
 b
e 
bo
un
d 
by
 a
ny
 a
dd
iti
on
al
 p
ro
vi
si
on
s 
th
at
 m
ay
 a
pp
ea
r 
in
 a
ny
 c
om
m
un
ic
at
io
n 
fr
om
 
Yo
u.
 T
hi
s 
Li
ce
ns
e 
m
ay
 n
ot
 b
e 
m
od
ifi
ed
 w
ith
ou
t 
th
e 
m
ut
ua
l w
ri
tt
en
 a
gr
ee
m
en
t 
of
 
th
e 
Li
ce
ns
or
 a
nd
 Y
ou
. 
 
C
re
at
iv
e 
C
om
m
on
s 
is
 n
ot
 a
 p
ar
ty
 t
o 
th
is
 L
ic
en
se
, 
an
d 
m
ak
es
 n
o 
w
ar
ra
nt
y 
w
ha
ts
oe
ve
r 
in
 
co
nn
ec
tio
n 
w
ith
 t
he
 W
or
k.
 C
re
at
iv
e 
C
om
m
on
s 
w
ill
 n
ot
 b
e 
lia
bl
e 
to
 Y
ou
 o
r 
an
y 
pa
rt
y 
on
 a
ny
 
le
ga
l 
th
eo
ry
 f
or
 a
ny
 d
am
ag
es
 w
ha
ts
oe
ve
r,
 i
nc
lu
di
ng
 w
ith
ou
t 
lim
ita
tio
n 
an
y 
ge
ne
ra
l, 
sp
ec
ia
l, 
in
ci
de
nt
al
 o
r 
co
ns
eq
ue
nt
ia
l d
am
ag
es
 a
ri
si
ng
 in
 c
on
ne
ct
io
n 
to
 t
hi
s 
lic
en
se
. 
N
ot
w
ith
st
an
di
ng
 t
he
 
fo
re
go
in
g 
tw
o 
(2
) 
se
nt
en
ce
s,
 i
f 
C
re
at
iv
e 
C
om
m
on
s 
ha
s 
ex
pr
es
sl
y 
id
en
tif
ie
d 
its
el
f 
as
 t
he
 
Li
ce
ns
or
 h
er
eu
nd
er
, 
it 
sh
al
l h
av
e 
al
l r
ig
ht
s 
an
d 
ob
lig
at
io
ns
 o
f 
Li
ce
ns
or
. 
 
Ex
ce
pt
 f
or
 t
he
 l
im
ite
d 
pu
rp
os
e 
of
 i
nd
ic
at
in
g 
to
 t
he
 p
ub
lic
 t
ha
t 
th
e 
W
or
k 
is
 l
ic
en
se
d 
un
de
r 
th
e 
C
C
PL
, 
ne
ith
er
 p
ar
ty
 w
ill
 u
se
 t
he
 t
ra
de
m
ar
k 
"C
re
at
iv
e 
C
om
m
on
s"
 o
r 
an
y 
re
la
te
d 
tr
ad
em
ar
k 
or
 
lo
go
 o
f 
C
re
at
iv
e 
C
om
m
on
s 
w
ith
ou
t 
th
e 
pr
io
r 
w
ri
tt
en
 c
on
se
nt
 o
f 
C
re
at
iv
e 
C
om
m
on
s.
 A
ny
 
pe
rm
itt
ed
 u
se
 w
ill
 b
e 
in
 c
om
pl
ia
nc
e 
w
ith
 C
re
at
iv
e 
C
om
m
on
s'
 t
he
n-
cu
rr
en
t 
tr
ad
em
ar
k 
us
ag
e 
gu
id
el
in
es
, 
as
 m
ay
 b
e 
pu
bl
is
he
d 
on
 i
ts
 w
eb
si
te
 o
r 
ot
he
rw
is
e 
m
ad
e 
av
ai
la
bl
e 
up
on
 r
eq
ue
st
 
fr
om
 t
im
e 
to
 t
im
e.
 
C
re
at
iv
e 
C
om
m
on
s 
m
ay
 b
e 
co
nt
ac
te
d 
at
 h
tt
p:
//
cr
ea
tiv
ec
om
m
on
s.
or
g/
.
«
B
ac
k 
to
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om
m
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D
ee
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